| Autor: |
Mills, K.H.G., Page, M., Chan, W.L., Kitchin, P., Stott, E.J., Taffs, F., Jones, W., Rose, J., Ling, C., Silvera, P., Corcoran, T., Flanagan, B., Burny, A., Bex, F., Delchambre, M., Van Opstal, O., Fabry, L., Thiriart, C., Delers, A., DeWilde, M., Bruck, C. |
| Zdroj: |
Journal of Medical Primatology; February 1992, Vol. 21 Issue: 2-3 p50-58, 9p |
| Abstrakt: |
Mills KHG, Page M, Chan WL, Kitchin P, Stott EJ, Taffs F, Jones W, Rose J, Ling C, Silvera P, Corcoran T, Flanagan B, Burny A, Bex F, Delchambre M, Van Opstal O, Fabry L, Thiriart C, Delers A, DeWilde M, Bruck C. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28‐derived recombinant env and gag proteins. J Med Primatol 1992:21:50‐58. Vaccination of cynomolgus macaques with β‐propiolactone inactivated SIVmacBK28in Freund's adjuvant induced low but detectable levels of anti‐SIV envelope (env) antibodies and T‐cell responses and protected against challenge with the 32H isolate of SIVmac251grown in C8166 cells. In contrast, purified recombinant SIV env and gag proteins derived from BK28 formulated in Syntex adjuvant generated consistent and long‐lived cellular and humoral immune responses to SIV env, but failed to protect against infection with the 32H virus. Thus, protection against a heterogeneous challenge stock is possible by immunization with a molecularly‐cloned virus, but not with recombinant proteins from the same molecular origin. High levels of anti‐cell antibodies induced by the whole virus vaccine, but not by recombinant proteins, may have contributed to the protection observed. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
